Alantra advised Biotay on its sale to Phibro Animal Health Corporation
Alantra advised the shareholders of Biotay S.A. on the sale of 100% of the shares to Phibro Animal Health Corporation.
Biotay is a leading animal health and nutritional products company founded in 1985 by former management of Eli Lilly & Co. in Argentina, engaged in production, marketing and distribution of products in Argentina and Uruguay. The company specializes in the bovine cattle, swine and poultry segments, and to a lesser extent horses and other species.
Juan Carlos Repetto, Biotay’s Chief Executive Officer, said in a recent public statement: “We are excited and looking forward to leveraging the strengths of both organizations and resources to better serve our customers, Phibro’s proven expertise and innovative platforms will provide strategic resources to maximize Biotay’s customer service capabilities, providing our customers with increased animal health, productivity and nutrition quality while improving animal welfare.”
The company owns an industrial plant and commercial offices in Argentina. The product portfolio consists of over 300 SKUs (Stock Keeping Unit), with approx. 600 clients. Biotay exports its products through representatives to more than six countries, mainly Uruguay, Bolivia and Paraguay.
Phibro is a global developer, manufacturer and marketer of animal health and mineral nutrition products for the poultry, swine, dairy, cattle and aquaculture markets. PAHC’s revenues and EBITDA reached US$764m and US$150m in LTM through June-2017, respectively. Market cap at the date of the transaction was US$1.34bn.
Oct 2020Buy-side advisoryOct 2020SECTOR HealthcareService M&A
Oct 2020InvestmentOct 2020SECTOR HealthcareService Strategic Advisory
Sep 2020Buy-side advisoryValue CHF 435 millionSep 2020SECTOR HealthcareService M&AValue CHF 435 million
Sep 2020Sell-side advisorySep 2020SECTOR HealthcareService M&A